COVx-RT_rendering-2048x1365

Rapid Results

Results in 15 minutes.

Improved Patient Outcomes

By providing faster results, medical professionals can offer earlier therapeutic interventions without needing additional resources or third party labs. Screening allows for limited resources to be used more efficiently.

Patient Friendly

Less invasive testing.

A quick process with minimal discomfort

No uncomfortable nasal swabs or invasive venous blood draw required. A quick finger prick and patients can be screened for IgM and IgG antibodies.

Immune Response

Infection staging

Qualitative Detection

While PCR tests may be able to determine pre-symptomatic, active, infections, they are not designed to detect antibodies indicative of a prior immune response.

Scalable & Efficient

Simple screening for triage environments.

Rapid Screening

When used as part of a larger screening protocol, lateral flow assays are an efficient way to screen for suspected COVID-19 positive patients.

For more information, contact our scientific support team at (844) 484-8372

The COVx-RT rapid test is designed for use by healthcare professionals. With 10 test kits per box, the COVx-RT rapid test saves valuable time and resources when screening large patient populations.

REQUEST QUOTE

Less Invasive Approach

Less invasive, COVx-RT requires only a few drops of blood from a simple finger prick to provide clear results in 15 minutes.

Testing Made Easy

A lateral flow immunoassay intended for qualitative detection and differentiation of IgM and IgG antibodies to SARS-CoV-2 in human serum and whole blood samples.

For Healthcare Professionals

The tests are easy to use with result indication at 15 minutes, allowing for efficient testing by healthcare professionals.

Test Specifcations

  • Specificity: 96%

  • Sensitivity: 91.4%

  • Overall Percent Positive Agreement (PPA): 94.1%

  • Overall Early Stage (IgM): 96.08%

  • Overall Late Stage (IgG): 98.04%
  • Sample Type: Whole Blood or Serum
  • Tested for cross-reactivity with 18 other pathogens with no false positivity or false negativity found.
  • Test Read Time: 15 minutes.
  • For Professional Use Only. Not for the Screening of Donated Blood.
  • This test has not been reviewed by the FDA.
  • 12 month shelf life. Do not freeze. Refrigeration not required.

Additional Resources

General information from the Government of Canada about COVID-19

Learn More

Healthcare Professional Resources from Canada.ca

Learn More

Instructions For Use

Learn More

This test is distributed in accordance with the most current FDA and Health Canada guidance. Notice has been submitted and the Vivera Pharma COVx-RT Rapid Test is currently on the FDA website under “Manufacturers that have notified FDA that they have validated and intend to distribute serology tests as set forth in Section IV.D” found at the following link: FDA Notification List under “Vivera Pharmaceuticals, Inc. COVx-RT.”

This test has been submitted for approval to Health Canada.THIS TEST IS NOT FOR THE SCREENING OF DONATED BLOOD.

  • THIS TEST HAS NOT BEEN REVIEWED BY THE FDA OR HEALTH CANADA.
  • FOR PROFESSIONAL USE ONLY IN QUALIFIED SETTINGS.
  • Negative results do not rule out SARS-CoV-2 infection, particularly in those who have been in contact with the virus. Follow-up testing with a molecular diagnostic should be considered to rule out infection in these individuals.
  • Results from antibody testing should not be used as the sole basis to diagnose or exclude SARS-CoV-2 infection or to inform infection status.
  • Positive results may be due to past or present infection with non-SARS-CoV-2 coronavirus strains, such as coronavirus HKU1, NL63, OC43, or 229E.
Verification

To place an order, we must verify you are a medical professional.

There will be a verification process in place.

REQUEST A QUOTE